EHR provider Practice Fusion has unveiled a first of its kind post-marketing active safety surveillance program within its EHR platform. The new active safety surveillance program can help facilitate Adverse Events of Special Interest (AESI) reporting by messaging healthcare providers directly at the point of care about AESIs their patients may have experienced during the course of therapy.
Post-Marketing Active Safety Surveillance Program Benefits
The post-marketing active safety surveillance program enables providers to monitor adverse events during the course of a patient’s treatment with prescription medications or other therapies. Using patient-level clinical characteristics, during a patient encounter, providers are notified through the Practice Fusion EHR when to screen patients for potential AESIs and how to facilitate AESI reporting following a patient encounter.
Rather than deploying a program to one medical practice at a time via the server-based model, Practice Fusion’s cloud-based model can rapidly integrate and deploy its active safety surveillance program to all practices using the company’s EHR. Practice Fusion’s connected digital health platform is used by over 30,000 practices — 6.4 percent of all practices in the U.S.1 — and has a separate de-identified clinical database, which includes over 38 million records containing rich clinical data.
“Our active safety surveillance program can be used to help satisfy important unmet needs for providers to more readily report AESIs at the point of care, for life sciences companies to work with providers to improve those companies’ post-market safety data collection, as well as for the U.S. Food and Drug Administration and the healthcare community to better understand the safety profile of approved therapeutics,” said Richard Loomis MD, Vice President and Chief Medical Officer at Practice Fusion.
